Effects of Resistant Starch on Symptoms,Fecal Markers,and Gut Microbiota in Parkinson's Disease—The RESISTA-PD Trial
- Author:
Becker ANOUCK
1
;
Schmartz Pierre GEORGES
;
Gr?ger LAURA
;
Grammes NADJA
;
Galata VALENTINA
;
Philippeit HANNAH
;
Weiland JACQUELINE
;
Ludwig NICOLE
;
Meese ECKART
;
Tierling SASCHA
;
Walter J?RN
;
Schwiertz ANDREAS
;
Spiegel J?RG
;
Wagenpfeil GUDRUN
;
Fa?bender KLAUS
;
Keller ANDREAS
;
M.Unger MARCUS
Author Information
1. Department of Neurology,Saarland University,D-66421 Homburg,Germany
- Keywords:
Parkinson's disease;
Short-chain fatty acid;
Microbiota;
Metagenomics;
Intestinal inflammation
- From:
Genomics, Proteomics & Bioinformatics
2022;20(2):274-287
- CountryChina
- Language:Chinese
-
Abstract:
The composition of the gut microbiota is linked to multiple diseases,including Parkin-son's disease(PD).Abundance of bacteria producing short-chain fatty acids(SCFAs)and fecal SCFA concentrations are reduced in PD.SCFAs exert various beneficial functions in humans.In the interventional,monocentric,open-label clinical trial"Effects of Resistant Starch on Bowel Habits,Short Chain Fatty Acids and Gut Microbiota in Parkinson's Disease"(RESISTA-PD;ID:NCT02784145),we aimed at altering fecal SCFAs by an 8-week prebiotic intervention with resistant starch(RS).We enrolled 87 subjects in three study-arms:32 PD patients received RS(PD+RS),30 control subjects received RS,and 25 PD patients received solely dietary instructions.We performed paired-end 100 bp length metagenomic sequencing of fecal samples using the BGISEQ platform at an average of 9.9 GB.RS was well-tolerated.In the PD+RS group,fecal butyrate concentrations increased significantly,and fecal calprotectin concentrations dropped significantly after 8 weeks of RS intervention.Clinically,we observed a reduction in non-motor symptom load in the PD+RS group.The reference-based analysis of metagenomes highlighted stable alpha-diversity and beta-diversity across the three groups,including bacteria producing SCFAs.Reference-free analysis suggested punctual,yet pronounced differences in the metagenomic signature in the PD+RS group.RESISTA-PD highlights that a prebiotic treatment with RS is safe and well-tolerated in PD.The stable alpha-diversity and beta-diversity alongside altered fecal butyrate and calprotectin concentrations call for long-term studies,also investigating whether RS is able to modify the clinical course of PD.
